Enter multiple symbols separated by commas

Abbott directors approve AbbVie split

Abbott Laboratories said its board of directors has approved a plan to spin off its pharmaceutical business into a separate company named AbbVie Inc.

The North Chicago, Ill., company also on Wednesday said that a special dividend will complete the separation of the business. Abbott shareholders will receive one share of AbbVie common stock for every share of Abbott they hold.

It will be paid Jan. 1 to Abbott shareholders as of Dec. 12. AbbVie stock is expected to start trading Jan. 2 on the New York Stock Exchange under the ticker symbol "ABBV," while Abbott shares will keep the "ABT" symbol.

AbbVie will focus solely on branded drugs, including top-seller Humira, an anti-inflammatory. The split is meant to free Abbott from the risks and obligations of developing pharmaceutical drugs, leaving it with a more predictable business built around nutritional formula, generic drugs and heart stents.

Abbott shares added 33 cents to $64.90 in premarket trading Thursday.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • In a rare menu test, Chipotle is testing a Chorizo Burrito, a spicy sausage made with chicken and pork, in its Kansas City restaurants.

    In a relatively a rare move for Chipotle Mexican Grill, Chipotle began testing a new menu item Tuesday.

  • A prototype of a Diebold bank branch of the future.

    Big banks are spending on futuristic branches, but it's all a waste of time and money, say financial technology experts.

  • Nouriel Roubini

    Nouriel Roubini explains how and why more economic liquidity may have led to "severe market illiquidity."

U.S. Video